Proton Therapy for Kidney Cancer

(SPARE Trial)

Overseen by Sherif Shaaban, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Research Team

Sherif Shaaban, MD

Principal Investigator

Johns Hopkins University

Eligibility Criteria

This trial is for adults over 18 with biopsy-proven renal cell carcinoma, which hasn't spread to other parts of the body. It's specifically for those who can't have surgery or local treatments and can undergo MRI or contrast CT scans.

Inclusion Criteria

I can have an MRI or a CT scan with contrast.

I am 18 years old or older.

My kidney cancer was confirmed through a biopsy.

Treatment Details

Interventions

• Proton Stereotactic Body Radiation therapy (SBRT) (Proton Beam Therapy)

Trial Overview The study is testing a type of targeted radiation called Proton Stereotactic Body Radiation Therapy (SBRT) to see how it affects kidney function and cancer outcomes like control of the tumor, spread, survival without progression, and overall survival.

Participant Groups

Group I: Proton Stereotactic Body Radiation Therapy (SBRT) Experimental Treatment 1 Intervention

The SBRT group is the single arm of this study.

Who Is Running the Clinical Trial?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Lead Sponsor

Trials

578

Recruited

33,600+

Dr. William G. Nelson

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Director since 1992

MD, PhD

Dr. Elizabeth Jaffee

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Chief Medical Officer since 2023

MD

Robert L. Sloan Fund for Cancer Research

Collaborator

Trials

5

Recruited

70+

Robert L. Sloan Fund for Cancer Research

Collaborator

Trials

5

Recruited

70+